Key result
Heparin-coated stenting shows no significant MLD gain over PTCA despite higher event-free survival.
Why the study?
The problems related to small-vessel stenting might be overcome using modern stents designed for small vessels combined with effective antiplatelet therapy, motivating an assessment of clinical and angiographic benefits compared with traditional PTCA.
Does elective stenting with a heparin-coated beStent improve minimal lumen diameter and clinical outcomes at 6 months compared with traditional PTCA in patients with stable or unstable angina and small coronary arteries (2.1-3.0 mm)?
RCT (n=145)
randomly assigned
Yes
Does elective stenting with a heparin-coated beStent improve minimal lumen diameter and clinical outcomes at 6 months compared with traditional PTCA in patients with stable or unstable angina and small coronary arteries (2.1-3.0 mm)?
Answers are grounded in this paper and cite their sources.
In small coronary arteries (2.1-3.0 mm), elective stenting with a heparin-coated beStent significantly improved 6-month event-free survival compared to PTCA, though the primary angiographic endpoint of minimal lumen diameter showed only a nonsignificant trend toward improvement.
OBJECTIVES: The purpose of this study was to assess the clinical and angiographic benefits of elective stenting in coronary arteries with a reference diameter of 2.1 to 3.0 mm, as compared with traditional percutaneous transluminal coronary angioplasty (PTCA). BACKGROUND: The problems related to small-vessel stenting might be overcome using modern stents designed for small vessels, combined with effective antiplatelet therapy. METHODS: In five centers, 145 patients with stable or unstable angina were randomly assigned to elective stenting treatment with the heparin (Hepamed)-coated beStent or PTCA. Control angiography was performed after six months. The primary end point was the minimal lumen diameter (MLD) at follow-up. Secondary end points were the restenosis rate, event-free survival and angina status. RESULTS: At follow-up, there was a trend toward a larger MLD in the stent group (1.69 +/- 0.52 mm vs. 1.57 +/- 0.44 mm, p = 0.096). Event-free survival at follow-up was significantly higher in the stent group: 90.5% vs. 76.1% (p = 0.016). The restenosis rate was low in both groups (9.7% and 18.8% in the stent and PTCA groups, respectively; p = 0.15). Analyzed as treated, both the MLD and restenosis rate were significantly improved in patients who had stents as compared with PTCA. CONCLUSIONS: In small coronary arteries, both PTCA and elective stenting are associated with good clinical and angiographic outcomes after six months. Compared with PTCA, elective treatment with the heparin-coated beStent improves the clinical outcome; however, there was only a nonsignificant trend toward angiographic improvement.
No takes yet. Share an insight, caveat, or question.
Moer et al. (2001) conducted an RCT in Stable or unstable angina with small coronary arteries (reference diameter 2.1 to 3.0 mm) (n=145). Elective stenting with heparin (Hepamed)-coated beStent vs. Traditional percutaneous transluminal coronary angioplasty (PTCA) was evaluated on Minimal lumen diameter (MLD) at six-month follow-up (p=0.096). Elective stenting with the heparin-coated beStent showed a nonsignificant trend toward larger MLD at 6 months vs PTCA but higher event-free survival.
Synapse has enriched 10 related papers. Consider them for comparative context: